BCYC
Bicycle Therapeutics plc NASDAQ Listed May 23, 2019$3.98
-0.50%
vs $4.00
Mkt Cap $275.7M
52w Low $3.98
0.0% of range
52w High $8.87
50d MA $4.60
200d MA $6.08
P/E (TTM)
-1.3x
EV/EBITDA
—
P/B
0.5x
Debt/Equity
0.0x
ROE
-35.9%
P/FCF
-1.1x
RSI (14)
26.90
ATR (14)
$0.19
Beta
1.65
50d MA
$4.60
200d MA
$6.08
Avg Volume
472.6K
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Babraham Research Campus · Cambridge, X0 CB22 3AT · GB
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | -0.62 | -0.87 | -40.1% | 4.73 | -1.5% | -0.2% | +1.7% | +2.9% | -0.8% | +5.1% | — |
| Mar 17, 2026 | BMO | -0.94 | -0.29 | +69.1% | 5.05 | +1.2% | +0.4% | -7.3% | -3.2% | -4.4% | -0.2% | — |
| Oct 30, 2025 | BMO | -1.09 | -0.85 | +22.0% | 8.18 | +0.0% | +7.1% | -7.9% | -10.0% | -5.4% | -10.2% | — |
| Aug 8, 2025 | BMO | -0.95 | -1.14 | -20.0% | 7.46 | +1.2% | +2.5% | -2.5% | -3.2% | +1.8% | +0.4% | — |
| May 1, 2025 | BMO | -0.86 | -0.88 | -2.3% | 8.56 | +1.6% | +6.1% | +2.4% | -2.6% | -18.3% | +5.1% | — |
| Feb 25, 2025 | BMO | -0.85 | -0.80 | +5.9% | 11.25 | +0.0% | -1.3% | +2.0% | -2.6% | -0.5% | -4.6% | — |
| Oct 31, 2024 | BMO | -0.78 | -0.74 | +5.1% | 24.03 | -3.0% | -2.4% | -3.2% | +3.3% | +0.2% | +0.6% | — |
| Aug 6, 2024 | BMO | -1.10 | -0.77 | +30.0% | 22.71 | -1.4% | +7.4% | -7.5% | +1.8% | +1.0% | -0.6% | — |
| May 2, 2024 | BMO | -1.26 | -0.62 | +50.8% | 24.20 | +3.0% | +2.0% | -0.4% | -5.2% | -0.9% | +2.3% | — |
| Feb 20, 2024 | BMO | -1.23 | -1.16 | +5.7% | 22.50 | -1.8% | +0.8% | +2.2% | +3.4% | +2.8% | +3.7% | — |
| Nov 2, 2023 | BMO | -1.06 | -1.26 | -18.9% | 15.35 | +3.4% | -2.9% | +4.2% | -5.4% | +3.8% | +0.6% | — |
| Aug 3, 2023 | BMO | -1.10 | -1.41 | -28.2% | 23.16 | -1.2% | -0.1% | +1.4% | -0.4% | -3.7% | -0.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $4.90 | $5.07 | +3.5% | +1.6% | -0.2% | -0.6% | +0.8% | +1.6% |
| Mar 18 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $5.07 | $5.12 | +1.0% | -7.3% | -3.2% | -4.4% | -0.2% | +3.7% |
| Mar 18 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.07 | $5.12 | +1.0% | -7.3% | -3.2% | -4.4% | -0.2% | +3.7% |
| Mar 18 | Citizens | Maintains | Market Outperform → Market Outperform | — | $5.07 | $5.12 | +1.0% | -7.3% | -3.2% | -4.4% | -0.2% | +3.7% |
| Mar 18 | Needham | Maintains | Buy → Buy | — | $5.07 | $5.12 | +1.0% | -7.3% | -3.2% | -4.4% | -0.2% | +3.7% |
| Oct 31 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $8.76 | $8.23 | -6.1% | -7.9% | -10.0% | -5.4% | -10.2% | +5.5% |
| Oct 31 | Citizens | Maintains | Market Outperform → Market Outperform | — | $8.76 | $8.23 | -6.1% | -7.9% | -10.0% | -5.4% | -10.2% | +5.5% |
| Aug 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $7.46 | $7.42 | -0.5% | -3.2% | +1.8% | +0.4% | +0.8% | +1.3% |
| Aug 12 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.46 | $7.42 | -0.5% | -3.2% | +1.8% | +0.4% | +0.8% | +1.3% |
| Aug 11 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.65 | $7.75 | +1.3% | -2.5% | -3.2% | +1.8% | +0.4% | +0.8% |
| Jul 17 | RBC Capital | Maintains | Outperform → Outperform | — | $7.78 | $7.66 | -1.5% | +3.3% | +6.5% | -2.9% | +0.7% | +4.1% |
| May 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $9.06 | $9.03 | -0.3% | -18.3% | +5.1% | +5.1% | +2.0% | +3.1% |
| May 2 | B. Riley Securities | Maintains | Neutral → Neutral | — | $9.08 | $9.44 | +4.0% | +2.4% | -2.6% | -18.3% | +5.1% | +5.1% |
| May 2 | RBC Capital | Maintains | Outperform → Outperform | — | $9.08 | $9.44 | +4.0% | +2.4% | -2.6% | -18.3% | +5.1% | +5.1% |
| May 2 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $9.08 | $9.44 | +4.0% | +2.4% | -2.6% | -18.3% | +5.1% | +5.1% |
| May 2 | Needham | Maintains | Buy → Buy | — | $9.08 | $9.44 | +4.0% | +2.4% | -2.6% | -18.3% | +5.1% | +5.1% |
| May 1 | Barclays | Maintains | Overweight → Overweight | — | $8.56 | $8.70 | +1.6% | +6.1% | +2.4% | -2.6% | -18.3% | +5.1% |
| Apr 29 | Needham | Maintains | Buy → Buy | — | $8.40 | $8.40 | +0.0% | -2.3% | +4.3% | +6.1% | +2.4% | -2.6% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $6.38 | $6.27 | -1.7% | +7.8% | -5.1% | +2.6% | +5.5% | +10.2% |
| Mar 11 | Needham | Maintains | Buy → Buy | — | $9.79 | $9.78 | -0.1% | +4.2% | +2.0% | -7.4% | +0.6% | +3.0% |
| Feb 26 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $11.10 | $11.09 | -0.1% | +2.0% | -2.6% | -0.5% | -4.6% | -3.2% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $11.10 | $11.09 | -0.1% | +2.0% | -2.6% | -0.5% | -4.6% | -3.2% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.10 | $11.09 | -0.1% | +2.0% | -2.6% | -0.5% | -4.6% | -3.2% |
| Jan 22 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $13.56 | $13.37 | -1.4% | -2.7% | +0.2% | -1.9% | +0.5% | +0.8% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $13.31 | $13.74 | +3.2% | +13.9% | -2.3% | -1.8% | -6.6% | -1.8% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.31 | $13.74 | +3.2% | +13.9% | -2.3% | -1.8% | -6.6% | -1.8% |
| Dec 18 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $15.14 | $16.47 | +8.8% | +1.2% | -2.1% | -2.1% | -1.0% | +1.0% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.81 | $13.88 | +0.5% | +9.5% | +0.1% | +1.2% | -2.1% | -2.1% |
| Dec 13 | B. Riley Securities | Maintains | Neutral → Neutral | — | $20.11 | $17.29 | -14.0% | -31.3% | +9.5% | +0.1% | +1.2% | -2.1% |
| Nov 1 | RBC Capital | Maintains | Outperform → Outperform | — | $23.45 | $23.31 | -0.6% | -3.2% | +3.3% | +0.2% | +0.6% | +4.5% |
| Nov 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.45 | $23.31 | -0.6% | -3.2% | +3.3% | +0.2% | +0.6% | +4.5% |
| Oct 31 | Needham | Maintains | Buy → Buy | — | $24.03 | $23.30 | -3.0% | -2.4% | -3.2% | +3.3% | +0.2% | +0.6% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.32 | $25.20 | -0.5% | -2.2% | -0.2% | +0.2% | -1.3% | -1.8% |
| Oct 24 | Needham | Maintains | Buy → Buy | — | $25.32 | $25.20 | -0.5% | -2.2% | -0.2% | +0.2% | -1.3% | -1.8% |
| Sep 16 | Needham | Maintains | Buy → Buy | — | $27.02 | $27.38 | +1.3% | -7.6% | -2.2% | -0.2% | +4.7% | -0.4% |
| Sep 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $27.02 | $27.38 | +1.3% | -7.6% | -2.2% | -0.2% | +4.7% | -0.4% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.02 | $27.38 | +1.3% | -7.6% | -2.2% | -0.2% | +4.7% | -0.4% |
| Sep 9 | Needham | Maintains | Buy → Buy | — | $20.54 | $21.00 | +2.2% | +28.3% | +2.5% | -0.3% | +1.0% | -0.8% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.38 | $23.48 | -3.7% | -7.5% | +1.8% | +1.0% | -0.6% | -2.9% |
| Aug 7 | Needham | Maintains | Buy → Buy | — | $24.38 | $23.48 | -3.7% | -7.5% | +1.8% | +1.0% | -0.6% | -2.9% |
| Aug 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $24.38 | $23.48 | -3.7% | -7.5% | +1.8% | +1.0% | -0.6% | -2.9% |
| Aug 7 | B. Riley Securities | Downgrade | Buy → Neutral | — | $24.38 | $23.48 | -3.7% | -7.5% | +1.8% | +1.0% | -0.6% | -2.9% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.69 | $25.33 | +2.6% | -0.4% | -5.2% | -0.9% | +2.3% | -0.2% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $23.07 | $22.77 | -1.3% | -0.3% | -2.1% | -0.9% | -2.2% | +0.5% |
| Feb 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.69 | $23.34 | +2.9% | +2.2% | +3.4% | +2.8% | +3.7% | +2.1% |
| Feb 21 | Canaccord Genuity | Maintains | Buy → Buy | — | $22.69 | $23.34 | +2.9% | +2.2% | +3.4% | +2.8% | +3.7% | +2.1% |
| Feb 21 | Needham | Maintains | Buy → Buy | — | $22.69 | $23.34 | +2.9% | +2.2% | +3.4% | +2.8% | +3.7% | +2.1% |
| Dec 20 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $17.81 | $18.00 | +1.1% | +1.5% | +1.6% | +1.6% | -0.3% | -0.6% |
| Dec 15 | Needham | Maintains | Buy → Buy | — | $15.00 | $14.98 | -0.1% | +16.7% | +1.1% | +0.6% | +1.5% | +1.6% |
| Nov 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $15.25 | $15.28 | +0.2% | +0.6% | -8.4% | -5.4% | +3.2% | +7.1% |
No insider trades available.
8-K
Bicycle Therapeutics plc -- 8-K Filing
Jun 18
8-K
Bicycle Therapeutics plc -- 8-K Filing
Bicycle Therapeutics' lead EphA2 candidate nuzefatide pevedotin shows promise across 150+ patients in oncology trials, potentially positioning the company competitively against existing cancer therapies.
Apr 30
8-K · 8.01
!! High
Bicycle Therapeutics plc -- 8-K 8.01: Material Event / Announcement
I need the actual content of the press release or announcement to provide a specific analysis of what this means for investors. The summary provided only references that a press release exists but doesn't describe the material event itself. Could you provide the actual announcement details?
Apr 20
8-K · 5.02
!!! Very High
Bicycle Therapeutics plc -- 8-K 5.02: Executive Change
Bicycle Therapeutics appointed Travis Thompson as CFO while he resigned from the board, indicating leadership restructuring that separates financial oversight from board governance roles.
Feb 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Acadian Asset Management Llc | 1,968,025 | $9M | Added | Mar 2026 |
| 2 | Candriam S.c.a. | 1,192,279 | $8M | Added | Dec 2025 |
| 3 | Principal Financial Group Inc | 1,148,272 | $8M | — | Dec 2025 |
| 4 | Gsk Plc | 1,529,561 | $7M | — | Mar 2026 |
| 5 | Morgan Stanley | 930,444 | $7M | Reduced | Dec 2025 |
| 6 | Renaissance Technologies Llc | 979,300 | $5M | Added | Mar 2026 |
| 7 | Schroder Investment Management Group | 615,833 | $3M | Added | Mar 2026 |
| 8 | Marshall Wace, Llp | 377,335 | $2M | Added | Mar 2026 |
| 9 | Citadel Advisors Llc | 377,085 | $2M | Added | Mar 2026 |
| 10 | Qube Research & Technologies Ltd | 308,617 | $1M | New | Mar 2026 |
| 11 | Millennium Management | 283,986 | $1M | Reduced | Mar 2026 |
| 12 | Rangeley Capital, Llc | 232,260 | $1M | Added | Mar 2026 |
| 13 | Pinnacle Associates Ltd | 185,410 | $860K | Reduced | Mar 2026 |
| 14 | Platinum Investment Management Ltd | 184,603 | $857K | — | Mar 2026 |
| 15 | Flax Pond Capital, Llc | 176,136 | $817K | New | Mar 2026 |
| 16 | Two Sigma Investments, Lp | 164,800 | $765K | Added | Mar 2026 |
| 17 | Monimus Capital Management, Lp | 93,840 | $664K | Added | Dec 2025 |
| 18 | Point72 Asset Management | 130,422 | $605K | Added | Mar 2026 |
| 19 | Persistent Asset Partners Ltd | 120,437 | $559K | New | Mar 2026 |
| 20 | Peapod Lane Capital Llc | 121,106 | $550K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 16
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Harbor Small Cap Growth Fund | 965,187 | $6M | Jan 2026 |
| 2 | SmallCap Fund | 567,800 | $4M | Jan 2026 |
| 3 | Old Westbury Small & Mid Cap Strategies Fund | 265,973 | $2M | Jan 2026 |
| 4 | iShares Biotechnology ETF | 244,101 | $1M | Mar 2026 |
| 5 | Multi-Manager U.S. Small Cap Equity Fund | 91,488 | $587K | Jan 2026 |
| 6 | Embark Small Cap Equity Fund | 40,802 | $262K | Jan 2026 |
| 7 | ALPS Medical Breakthroughs ETF | 44,503 | $255K | Feb 2026 |
| 8 | Virtus LifeSci Biotech Clinical Trials ETF | 37,816 | $243K | Jan 2026 |
| 9 | VOYA MULTI-MANAGER INTERNATIONAL SMALL CAP FUND | 30,052 | $193K | Jan 2026 |
| 10 | Fidelity Nasdaq Composite Index Fund | 25,129 | $144K | Feb 2026 |
| 11 | Harbor Health Care ETF | 15,017 | $96K | Jan 2026 |
| 12 | Invesco NASDAQ Future Gen 200 ETF | 8,851 | $51K | Feb 2026 |
| 13 | Harbor International Core Fund | 6,102 | $39K | Jan 2026 |
| 14 | Invesco Nasdaq Biotechnology ETF | 2,589 | $15K | Feb 2026 |
| 15 | ProShares Ultra Nasdaq Biotechnology | 2,136 | $12K | Feb 2026 |
| 16 | iShares Health Innovation Active ETF | 392 | $3K | Jan 2026 |
Valuation
Market Cap
$275.7M
Enterprise Value
-$352.4M
P/E (TTM)
-1.26x
Forward P/E
—
PEG Ratio
-0.26x
P/B
0.45x
P/S
4.34x
P/FCF
-1.09x
EV/EBITDA
—
Shares Out
69.3M
Financials (TTM)
Revenue
$63.5M
Net Income
-$219.0M
EBITDA
-$211.5M
Free Cash Flow
-$252.6M
Op Cash Flow
-$249.7M
EPS Basic
$-3.16
EPS Diluted
$-3.15
EPS Forward
$-2.09
Gross Margin
-11.9%
Op Margin
-381.8%
Net Margin
-344.9%
Balance Sheet
Total Assets
$717.6M
Total Liab.
$107.6M
Total Equity
$610.0M
Cash
$628.1M
LT Debt
$0
Book Value/Sh
$8.80
Debt/Equity
0.03x
Current Ratio
11.02
Quick Ratio
11.02
Returns & Growth
ROE
-35.9%
ROA
-30.5%
ROIC
-37.2%
Rev Growth YoY
+105.8%
EPS Growth YoY
-8.6%
Price Returns
2W
+0.4%
1M
-0.6%
3M
-18.2%
6M
-37.3%
12M
-42.9%
Technicals
52W High
$8.87
52W Low
$3.98
50d MA
$4.60
200d MA
$6.08
RSI (14)
26.90
ATR (14)
$0.19
Beta
1.65
Avg Volume
473K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$10.67
High
$12.00
Low
$8.00
Median
$12.00
Data updated apr 26, 2026 9:50am
· Source: financialmodelingprep.com